Figure 9
From: THEM6 is a prognostic biomarker for breast cancer and is associated with immune infiltration
Cell-based assays were conducted to confirm the function of THEM6 in breast cancer cells. (A) qPCR detection of transfection efficiency in BT549 and HCC1806 cell lines in which knockdown experiments were performed. Transfection efficiency of si-THEM6-1 and si-THEM6-2 was the greatest among three siRNAs; (B) CCK-8 detection shows that reduced expression of THEM6 inhibits the proliferation of BT549 and HCC1806 breast cancers; (C) Transwell experiments revealed that BT549 and HCC1806 breast cancer cells had significantly reduced migration ability after THEM6 silencing; (D) Suppression of BT549 and HCC1806 cell survival by knockdown of THEM6; (E) Effects of silencing THEM6 followed by flow cytometry analysis of BT549 and HCC1806 cell cycles.
